Skip to content

Pattern and Outcomes of Chest Diseases

Pattern and Outcome of Respiratory Diseases in Patients Admitted in the Chest Department at Assiut University Hospital

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06053528
Enrollment
2000
Registered
2023-09-25
Start date
2023-10-01
Completion date
2024-12-01
Last updated
2023-09-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chest--Diseases

Brief summary

The objective of this study is to determine the pattern and outcome of respiratory diseases in adults patients admitted to the Department of Chest Diseases at Assiut University Hospital.

Detailed description

Respiratory diseases constitute an important global health burden. Pneumonia, tuberculosis, obstructive and restrictive lung diseases, pleural diseases, and malignancies are common respiratory conditions for hospital admission.Before the emergence of COVID-19, pneumonia, including community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP)/ventilation-associated pneumonia (VAP), was one of the most common infectious diseases, and could cause major health problems, associated with high morbidity and mortality in all age groups worldwide . The outbreak of COVID-19 has significantly changed the epidemiology of respiratory tract infection. More than 376 million people have been infected and 5 million have died in the whole world. This in addition to the long term post COVID pulmonary sequelae. Chronic obstructive pulmonary disease (COPD), lower respiratory tract infections, lung cancer and tuberculosis have been identified as top four respiratory diseases among ten leading causes of death worldwide. The forum of international respiratory societies (FIRS) estimated that 65 million people have moderate to severe COPD resulting in 3 million deaths per year, making it third leading cause of death worldwide .Currently, asthma affects an estimated 334 million people worldwide and is projected to increase to 400 million by the year 2025 . In ;2015 10,4million people developed TB with 1.4 million global deaths were reported. Neoplasms of the lungs are the leading cause of cancer incidence and mortality worldwide.

Interventions

DRUGAntibiotic

Effect if treatment

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years

Inclusion criteria

* All adults patients admitted to the Chest Department during the study period will be included.

Exclusion criteria

* Patients who will die, be discharged, or be transferred before completing data collection will be excluded from our study.

Design outcomes

Primary

MeasureTime frame
Determine number of patients who experience improvement on dischargeOne year
Number of patient who Transferred to another hospital forcontintreatmentOne year
Number of patient died while on admissionOne year
Number of patient who Discharged against medical adviceOne year

Contacts

Primary ContactFatma Hamdan Zaki, Resident doctor
fhamdan714@gmail.com01068769640
Backup ContactAmany Omar, Professor of Chest Disease
amanyomd@aun.edu.eg01112524249

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026